TAIPEI, Taiwan, May 30, 2017 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that it has submitted a New Drug Application (NDA) for the intravenous formulation of Taigexyn® (Nemonoxacin) to the China Food and Drug Administration (CFDA). Taigexyn® is a novel non-fluorinated quinolone antibiotic. The NDA submission is supported by a pivotal Phase 3 trial comparing intravenous formulations of Taigexyn® 500 mg to levofloxacin 500 mg in 518 patients with moderate to severe community-acquired pneumonia. The clinical success rates were 91.8% for Taigexyn® vs. 85.7% for levofloxacin and Taigexyn® was shown to be non-inferior to levofloxacin meeting the primary endpoint of the pivotal trial.
Taigexyn® is a novel broad spectrum antibiotic with excellent efficacy against drug-resistant bacteria available in both oral and intravenous formulations. The oral formulation is already approved for marketing and launched in Taiwan and mainland China. In addition, Taigexyn® is also partnered in Russia, Commonwealth Independent States, Turkey, Mexico, Brazil and the Latin American territory for a total 32 countries worldwide.
About TaiGen Biotechnology
TaiGen Biotechnology, a public listed company in Taipei Exchange (4157.TWO), is a leading research-based biotechnology company in Taiwan. In addition to Taigexyn®, TaiGen has two other in-house discovered NCEs in clinical development: TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infection, and TG-0054, a chemokine receptor antagonist for hematopoietic stem cell transplantation and chemosensitization.
For more information please contact:
Peter W. Tsao, PhD, Sr. Vice President Business Development